In humans, DPP-4is, including sitagliptin, have demonstrated the ability to decrease systemic inflammatory mediators, including C-reactive protein (CRP) and interleukin-6 (IL-6) and other inflammatory markers in human patients with T2DM in clinical trials [80,81]. This evidence concerns the gene CRP and type 2 diabetes mellitus.